255 related articles for article (PubMed ID: 37978132)
21. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
23. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
[TBL] [Abstract][Full Text] [Related]
24. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
Pham MM; Avila M; Hinchcliff E; Westin SN
Cancer Treat Res; 2023; 186():71-89. PubMed ID: 37978131
[TBL] [Abstract][Full Text] [Related]
25. Targeting BRCA and PALB2 in Pancreatic Cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of PARP inhibitors in breast cancer.
Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
[TBL] [Abstract][Full Text] [Related]
27. Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
Desai NV; Tung NM
Breast J; 2020 Aug; 26(8):1506-1512. PubMed ID: 32633033
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitor treatment of advanced breast cancer beyond the
Yan F; Jiang Q; He M; Shen P
Future Oncol; 2021 Jun; 17(18):2381-2393. PubMed ID: 33784822
[TBL] [Abstract][Full Text] [Related]
29. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
[TBL] [Abstract][Full Text] [Related]
30. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
31. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Oh SY; Rahman S; Sparano JA
Expert Opin Pharmacother; 2021 Jun; 22(8):981-1003. PubMed ID: 33646064
[No Abstract] [Full Text] [Related]
32. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
33. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
35. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
36. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
37. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
39. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Ashworth A; Lord CJ
Nat Rev Clin Oncol; 2018 Sep; 15(9):564-576. PubMed ID: 29955114
[TBL] [Abstract][Full Text] [Related]
40. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
